Medical Devices · NYSE: ZBH
Zimmer Biomet earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 9 Feb 2027
Latest: Q3 2026
Zimmer Biomet says its diversification strategy is working, as Hips, S.E.T. and Technology & Data grew at upper single or double digits while Knees shrank, and it extended its THINK Surgical robotics deal.
Zimmer Biomet's growth is shifting away from knees. Hips, S.E.T. and Technology & Data, Bone Cement and Surgical grew at upper single-digit or double-digit rates and together make up two-thirds of the business, while Knees declined in both the U.S. and internationally. The company extended its multi-year distribution and supply agreement with THINK Surgical, launched foot and ankle products, and opened a surgeon training facility in Charlotte.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.0B * |
| Q1 2025 | $1.9B |
| Q2 2025 | $2.1B |
| Q3 2025 | $2.0B |
| Q4 2025 | $2.2B * |
| Q1 2026 | $2.1B |
| Q2 2026 | $2.2B |
| Q3 2026 | $2.1B |
Data
| Q1 2025 | $0.91 |
| Q2 2025 | $0.77 |
| Q3 2025 | $1.16 |
| Q1 2026 | $1.22 |
| Q2 2026 | $1.03 |
| Q3 2026 | $1.00 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 19.2% |
| Q1 2025 | 15.3% |
| Q2 2025 | 14.4% |
| Q3 2025 | 17.6% |
| Q4 2025 | 6.9% |
| Q1 2026 | 17.9% |
| Q2 2026 | 15.0% |
| Q3 2026 | 14.9% |
Data
| Q4 2024 | $454.8M |
| Q1 2025 | $338.2M |
| Q2 2025 | $328.1M |
| Q3 2025 | $363.7M |
| Q4 2025 | $442.6M |
| Q1 2026 | $323.1M |
| Q2 2026 | $393.6M |
| Q3 2026 | $484.2M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0Bd | $1.9B | $2.1B | $2.0B | $2.2Bd | $2.1B | $2.2B | $2.1B |
| Operating income | $389.0Md | $292.3M | $300.0M | $351.3M | $154.5Md | $373.2M | $326.1M | $307.6M |
| Operating margin | 19.2% | 15.3% | 14.4% | 17.6% | 6.9% | 17.9% | 15.0% | 14.9% |
| Net income | $239.5Md | $182.0M | $152.8M | $230.9M | $139.3Md | $238.1M | $198.3M | $191.6M |
| Diluted EPS | — | $0.91 | $0.77 | $1.16 | — | $1.22 | $1.03 | $1.00 |
| Operating cash flow | $506.3Md | $382.8M | $378.2Md | $418.7Md | $517.4Md | $359.4M | $447.8Md | $560.0Md |
| Capital expenditure | $51.5Md | $44.6M | $50.1Md | $55.0Md | $74.8Md | $36.3M | $54.2Md | $75.8Md |
| Free cash flow | $454.8M | $338.2M | $328.1M | $363.7M | $442.6M | $323.1M | $393.6M | $484.2M |
| R&D expense | $108.5Md | $110.6M | $113.3M | $115.9M | $118.7Md | $103.4M | $104.8M | $105.9M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 4 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 5 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 1 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 20 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 5 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 7 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 5 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 25 Feb 202510-K for the period ended 31 Dec 2024SEC ↗